Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Next Previous
Search
Trial Profile

A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NGM 621 (Primary)
  • Indications Dry age-related macular degeneration; Dry macular degeneration
  • Focus Adverse reactions; First in man
  • Sponsors NGM Biopharmaceuticals

    • Most Recent Events

    • 01 Mar 2022 Results published in the American Journal of Ophthalmology
    • 06 May 2021 According to a NGM Biopharmaceuticals media release, additional data from this study were presented in an oral presentation at the Angiogenesis, Exudation, and Degeneration 2021-Virtual Edition.
    • 09 Feb 2021 According to a NGM Biopharmaceuticals media release, additional data from the study will be presented in an oral presentation at the Angiogenesis, Exudation, and Degeneration 2021-Virtual Edition. The presentation will be available on the NGM Bio website.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top